Breakthrough device reimbursement rule on the rocks
Despite industry outcry, new data question how relevant the rule would have been anyway.
Jaks capped in arthritis – but the FDA might not be finished
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Biogen and the social contract
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Dangling PD-1s emerge strong from three-day grilling
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Europe needs to be clearer about Covid-19 vaccines
Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
